Overall, the data presented in this study suggest that the PDE4 inhibitor Tanimilast could be a promising inhaled immunomodulator in the scenario of COVID-19, given its remarkable safety demonstrated in healthy subjects as well as in asthma and COPD patients (14) and its mechanism of action non redundant with corticosteroids. This evidence concerns the gene PDE4A and COVID-19.